Health-related quality of life and hemoglobin levels in chronic kidney disease patients

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 1, 2009, Pages 33-38

  Finkelstein, Fredric O ^a   Story, Kenneth ^b   Firanek, Catherine ^b   Mendelssohn, David ^c   Barre, Paul ^d   Takano, Tomoko ^d   Soroka, Steven ^e   Mujais, Salim ^f  

^a YALE UNIVERSITY   (United States)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c Humber Mem Hosp   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^f ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; BIOLOGICAL MARKER;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TREND STUDY; BLOOD; CANADA; CHRONIC DISEASE; HOSPITALIZATION; KIDNEY DISEASE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

AGED; ANEMIA; BIOLOGICAL MARKERS; CANADA; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 64049119171     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00630208     Document Type: Article

References (14)

1. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006 Nov 16 (Pubitemid 44749316)
2. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reeddan D, CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006 (Pubitemid 44749317)
3. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 27: 584-590, 1998 (Pubitemid 28385655)
4. U.S. Food and Drug Administration Center for Drug Evaluation and Research: Advisory. November 8, 2007
5. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300: 573-578, 1990
6. Perlman R, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, Burrows-Hudson S, Messana JM, Levin N, Rajjagopalan S, Port FK, Wolfe RA, Saran R: Quality of life in chronic kidney disease (CKD): A cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 45: 658-666, 2005 (Pubitemid 40460754)
7. Lopes AA, Bragg-Gresham JL, Goodkin DA, Fukuhara S, Mapes DL, Young EW, Gillespie BW, Akizawa T, Greenwood RN, Andreucci VE, Akiba T, Held PJ, Port FK: Factors associated with health-related quality of life among hemodialysis patients in the DOPPS. Qual Life Res 16: 545-557, 2007 (Pubitemid 46474941)
8. Mapes DL, Lopes AA, Satayathuym S, McCullough KP, Goodkin DA, Locatelli F, Fukuhara S, Young EW, Kurokawa K, Saito A, Bommer J, Wolfe RA, Held PJ, Port FK: Health-related quality of life as a predictor of mortality and hospitalization: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 64: 339-349, 2003 (Pubitemid 36714189)
9. Korevaar JC, Merkus MP, Jansen MAM, Dekker FW, Boeschoten EW, Krediet RT, NECOSAD Study Group: Validation of the KDQofL-SF: A dialysis-targeted health measure. Qual Life Res 11: 437-447, 2002
10. Ware J, Kosinski M, Keller S: SF36 Physical and Mental Health summary scales. A User's Manual, 2nd Ed., Boston, The Health Institute, New England Medical Center, 1994
11. Lefebvre P, Vekeman F, Sarokham B, Enny C, Provenzano R, Cremieux PY: Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin 22:1929-1937, 2006
12. Provenzano R, Garcia-Mayol L, Suchinda P, von Hartitzsch B, Woollen SB, Zabaneh R, Fink JC, POWER Study Group: Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 61:392-405, 2004 (Pubitemid 38787334)
13. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, Benz RL: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25:548-554, 1995
14. Hartwell L: Testimony before the U.S. Food and Drug Administration, September 11, 2007, as reported by the Renal Support Network. Available at: http://www.asnonline.org/newsletter/renal-policy-express/2007/ Special%20Edition-FDA%20Hearing.aspx